Hemispherx (wkn:906543): - 500 Beiträge pro Seite

[FrankaZiemer]

Bei wallstreet Online heute folgende Meldung zu lesen:

Das biopharmazeutische Unternehmen Hemispherx Bio Pharma (Amex: HEB) gab heute bekannt, dass man weiterhin voller Besitzer des Hepatitis-Geschäftsbereich bleiben werde. Hemispherx hatte geplant, diesen Bereich als „Targeted“ oder „Tracking Stock“ auszugliedern.

Das Unternehmen sagte, dass die klinischen Kapazitäten der Europäischen Tochter Hemispherx BioPharma Europe nun eine effiziente Durchführung von Phase II/III-Tests erlauben. Der Spin-Off sei dadurch nicht mehr nötig.

Hepatitis B und C gehören zu gravierenden Problemen in Gesundheitsbereich, vor allem in der Europäischen Union. Entsprechend einer beschleunigten Rate von viralen Mutationen beherbergen viele Patienten Hepatitis-Viren, die resistent gegenüber einer Ersttherapie durch Interferon Alpha sind. Mit den Hemispherx-Hepatitis-Arzneien Ampligen (Phase I/II) Polyadenur (Phase II/III), Oragens (vorklinisch) und CIMM (vorklinisch) könnte die Resistenz gegenüber Interferon Alpha gedämmt werden.

Die Aktien des Unternehmens können heute um 4 Prozent auf 6-1/2 US-Dollar zulegen.


Hatte diesen Wert schon länger auf meiner Biotech Watchlist und bin heute eingestiegen!
Wer von Euch ist noch dabei, oder beobachtet den Wert???
Liebe Grüsse und auf einen satten BiotechWinter!
Franka

[Der Pharmer]

Hier, ich bin dabei.

Bin Anfang März zu 16,80 Euro rein, weil der Börsenbrief
ADM (Aktie der Monats) sehr überzeugend über Hemispherx
geschrieben hat. - Leider zum falschen Zeitpunkt.

Aber was soll`s. - Die wurden natürlich ausgestoppt.
Hab` selber aber kein Stopp-Loss angegeben, weil ich langfristig
orientiert bin.

Wenn die Erfolg haben mit ihrem Ampligen,
dann sehen wir ganz schnell 3-stellige Kurse.
Dann ist auch egal, ob man bei 16 oder bei 7 Euro gekauft hat.
So seh` ich das jedenfalls.

Enorm ist natürlich auch die Fantasie, die in dem
Wert steckt. Und da werden wir sicher die nächste Ralley im Herbst
sehen, so oder so, mit oder ohne FDA !!!

Euer Hemispherx Biopharmer

[nendaz]

hallo @franka, hallo@pharmer

bin auch noch mit einer kleinen position seit märz dabei. zu 10€ eingestiegen aber genau wie pharmer hoffe ich auf (wahrhaftig) durchschlagende wirkung ampligens, zum wohle der patienten und der aktionäre.

ich verfolge heb regelmäßig in den us-boards ragingbull und yahoo und im multexinvestor. scheinen eine menge belgier in dem wert drin zu sein.

falls ich was neues finde, wirds sofort gepostet.

viele grüße, nendaz(übrigens ein skiort, wallis/CH!)

[FrankaZiemer]

Nur drei Aktionäre hier bei Wallstreet-O.???
Kann ich kaum glauben bei einem ambitionierten Biotechwert!
Naja egal, wer Infos hat postet sie halt, vielleicht werden es ja noch mehr, sind momentan ja immerhin super Einstiegskurs finde ich und außerdem werden heute wieder paar Stücke in NY gekauft!
Liebe Grüsse von Franka

[Dr.Info]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[götz]

Hallo Franka,
Wohl eine Potente Entscheidung, sich in HEB zu engagieren. Hoffentlich werden aus den vielen Phase
II/III Tests bald Zulassungen..... Infos zu HEB findest Du auch unter messages.yahoo.com, HEB eingeben.
Du solltest Dir die Charaktere, die dort auftreten, jedoch eine Weile ansehen, bevor Du Dich dazu
entschließt, irgendwas zu glauben.

Gruß
Götz (auch bei HEB engagiert, sollte vielleicht nochmal nachkaufen...)

[FrankaZiemer]

Heute lief der Gesamtmarkt in NY ja nicht gerade gut, aber Hemispherx mit einem sehr erfreulichen Plus von fast 8 Prozent, das sieht doch schonmal ganz gut aus!
Liebe Grüsse von Franka

[Der Pharmer]

Hallo Hemis-Aktionäre,

Habe beobachtet, daß HEB in der Kursentwicklung der Nasdaq
oder dem Nasdaq-Biotech-Index immer ein paar Tage hinterherhinkt.

HEB wird ja bekanntlich an der AMEX gehandelt.

Habt Ihr das auch bemerkt ??

Grüße,
Der Biopharmer

[nendaz]

hallo HEB`ler

1 neue SHIV grundlagenforschung mit HEB eigenen RNAs

Hemispherx Biopharma Launches New Program to Enhance Potential HIV Vaccines in Primates
PHILADELPHIA--(BW HealthWire)--July 13, 2000--Hemispherx Biopharma, Inc. (AMEX:HEB - news) announced a new program to enhance certain HIV vaccines being developed in primate models and described at the ongoing 13th International AIDS Conference, Durban, South Africa.
The Company said that the impetus for the new programs derives from European-based animal studies. In these studies, certain RNA-type drugs, patented and being developed by Hemispherx, increased host immunity against certain viruses, including influenza and hepatitis. Enhanced immunity occurred after the RNA`s were administered either by nasal sprays or injection. Hemispherx owns outright, or is the exclusive licensee, of some 40 unique synthetic RNA`s. Naturally occurring RNA`s (ribonucleic acids) are the body`s primary portfolio of ``informational molecules`` which switch `on` or `off` various cell functions.
In the proposed primate vaccine studies, SHIV (Simian human immunodeficiency virus) models will be used with one or more human vaccines under consideration. The SHIV`s elicit a predictable disease response in the primate, and the overall objective will be to try boosting the efficacy of the vaccine candidates.
Immunity can generally be boosted by augmenting either of the two basic arms of the immune response -- namely the humoral (blood-borne) or cellular (fixed at portal of entry) responses. Recent studies at the Johns Hopkins University indicate that the concentration of certain RNA`s, owned by Hemispherx, may be critical to effective switching `on`, or `off`, of certain components of the immune system.
An objective of the proposed program will also be to increase `memory` capacity of different types of immune cells such that disease can be prevented in immunized primates or ameliorated in animals already experiencing ongoing SHIV infection.
Compounds given along side vaccine preparations are sometimes termed ``adjuvants`` in that they augment the potential benefit of the vaccine in either uninfected (``naive``) or already infected animals. The degree of progress in overall vaccine research was summarized at the 13th International AIDS Conference; generally, the need for better protection, including that potentially conveyed by the adjuvants, and better `memory` was emphasized.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders.

Contact:
Hemispherx Biopharma, Inc.
William A. Carter, M.D., 215/988-0080
www.hemispherx.com
or
Investor Relations
Dianne Will, 214/954-9300
Fax: [phone]
or
Institutional Investors
Mark Kollar, 212/232-2222
Fax: [phone]

der interessante part ist nicht unbedingt, daß HEB neue SHIV versuche startet, sondern daß HEB offensichtlich patente auf oder exklusivrechte an 40 verschieden RNAs (Ribonukleinsäuren) besitzt, die alle entscheidend für zellsteuerungsprozesse sind und damit ein potentiell großes einsatzspektrum versprechen.

es ist alles eine frage der zeit und des geldes.

die absage der auslagerung der europäischen hepatitis sparte HEB`s könnte auch in diesem zusammenhang positiv gesehen werden. Entweder ist genug eigenkapital vorhanden oder forschung ist derart vielversprechend, daß die notwendige unterstützung von investoren besteht.

ich halte weiter an HEB fest und baue auf die zukunft!

2 falls diese information schon kam, vergessen!
interessante seite ist www.hotstocks.com und dann das gewünschte aktienkürzel eingeben. über diese seite gelangt man auch direkt auf die message-boards von yahoo und raging bull zu den gesuchten werten.


gruß, nendaz

[FrankaZiemer]

Hi Leute, noch dabei???
Nachdem ich die letzten tage sehr hart an meinem großen Anteil von Blue C in meinem Depot zu knabbern habe, kann ich mich momentan wenigstens etwas über Hemispherx freuen, sieht doch wirklich sehr gut aus!
Grüsse von Franka!

[mamomilano]

FDA to Receive Public Testimony on Immune Based Therapies for HIV -- Oct 16 2000
NEW YORK, Oct 16, 2000 /PRNewswire via COMTEX/ -- Over the past 14 months, AIDStreatment activists, many of whom are members of The HIV Immune Based TherapyWorking Group have placed pressure on the Food and Drug Administration regardingthe FDA process, procedures and review of immune based therapies for thetreatment of HIV disease. In a surprise turn of events by the FDA AntiviralCommittee, a meeting is scheduled to take place Oct. 16 to discuss these issues.The pressure placed on the FDA by AIDS treatment activists over the past 14months about the review process of immune based therapies including IL-2, madeby Chrion, and Ampligen, made by Hemispherx Biopharma is coming to a head todayas a controversial meeting, held in Washington D.C. and open to the public, isconvening to discuss how the Antiretroviral committee should proceed in itsreview of these therapeutic options for people with AIDS."The FDA has been slow to acknowledge that there is a lack of meritorious reviewprocedures in place to ensure scientifically valid consideration of theseclinical options," said Jeannie Gibbs of the IBT Working Group.The FDA posted a notice (with limited distribution) about the proposed contentsof the meeting.It is hoped by many AIDS treatment activists that the FDA will use thisopportunity to begin to catch up with the rest of the clinical communityinvolved in HIV research and allow for some strong determining results that willencourage the development of valid clinical research on immune restoration forHIV disease.For more information on this meeting please contact: Nancy Chamberlin, orBeverly O`Neil, Center for Drug Evaluation and Research (HDF-21), Food and DrugAdministration, 5600 Fishers Lane, (for express delivery) 5630 Fishers Lane Rm.1093) Rockville, MD 20857, or by e-mail: [e-mail]. Contactpersons can be reached by telephone at 301-827-7001.For more information contact: Alanzo Massee, HIV Immune Based Therapy WorkingGroup at 718-299-9429.SOURCE HIV Immune Based Therapy Working Group CONTACT: Alanzo Massee of the HIV Immune Based Therapy Working Group, 718-299-9429


Endlich wirkt sich mal der Druck der Aidsresearcher auf die Trantüten der FDA aus.
Gruss von eurem
Mamomilano

[fatbull]

Dieser Beitrag ist von LarryL vom09.04.99!!!!!
Habe diesen Dino der Biotechs ausgegraben weil die Produktpipeline
aus 99 sich jetzt schon in weiteren Phasen befindet so das in nächster Zeit einige Produkte marktreife erlangen werden.

mfg fatbull



Hemispherx Biopharma Inc.

Hintergrund
HEB wurde ergründet und wird geleitet von Dr. Wiliam Carter einem der Pioniere der INTERFERON Therapie (Natürliches, vom Körper erzeugtes Mittel gegen Virus-Infektionen, kann auch künstlich hergestellt werden). Er eignete sich über 3 Jahrzente theoretisches und praktisches Wissen in der Erforschung von „nucleid acid (NA) compounds“ (genetisch erzeugbare Mittel zur Bekämpfung von chronischen Virus-Infektionen. HEB ist das einzige Unternehmen, deren Wissenstand so fortgeschritten ist, um NA-technology wirksam einzusetzen. Das Unternehmen hat sich weltweit über 300 Patente gesichert, und ist damit führend unter allen Pharmakonzernen.

Das Kernprodukt von HEB ist Ampligen, welches wirksam in der Bekämpfung von Krankheiten, welche das Immun-System schädigen und schwächen wie z.B. CFS (Chronic Fatigue Syndrom), HIV und Hepatitis B.

Es ist bewiesen, dass Ampligen das einzige Mittel zur Bekämpfung von CFS ist. CFS ist eine komplexe Krankheit welche tiefe Müdigkeit, Schlafstörungen und Muskelschmerzen hervorruft. In 30 % aller Fälle führt sie bis zur Bettlägerigkeit und Pflegefall. Alleine in den USA gibt es 600.000 Betroffene und in Europa noch einmal 600.000. Anhand einer Studie der Harvard Universität liegt die Anzahl der Betroffenen Amerikaner bei 2.500.000.

CFS wurde vor kurzen in die Liste der „Priorität 1“ Krankheiten eingetragen, dort handelt es sich um Krankheiten, welche noch nicht mit Medikamenten heilbar sind, wie z.B. AIDS.

Die Behandlung von CFS ist derzeit in PHASE III fortgeschritten und in das Programm Treatment IND aufgenommen (Treatment investigational new drug). Dieses Programm unterstützt HEB um umfangreiche Testreihen in der Behandlung von CFS mit Ampligen durchzuführen und die FDA übernimmt dabei einen Grossteil der Kosten. HEB hat sich auch als einziges Unternehmen weltweit die Lizenz gesichert um Ampligen zu verkaufen.

Im Falle eines steigenden Interesses von Investoren, wäre HEB derzeit mit 14 $ fair bewertet, da andere vergleichbare Pharmaunternehmen mit gleich- oder weniger-vielversprechenden Aussichten um mehr als das vierfache höher gehandelt werden.

Wir glauben, dass auf der Basis einer kompletten FDA-Zulassung von Ampligen, die Aktie ein Potential von 50 $ hat.

HEB hat vor kurzem zwei „Senior executives“ eingestellt um die Expandierung nach Europa zu beschleunigen, des weiteren wird es in naher Zukunft ein paralleles Listing am NEUEN MARKT und an der EASDAQ geben.

NUCLEIC ACID Pharmaceuticals-Ampligen

Ribonucleic acid (RNA) ist eine natürliche Gruppe von Informations-Molekülen welche das Verhalten von Zellen steuern, eingeschlossen deren Zellen die das menschliche Immunsystem steuern.

Hemispherx erforschte eine Substanz basierend auf künstlichem RNA. Die Substanz heisst AMPLIGEN.

Ampligen ruft eine eine Anti-Virus-Reaktion im menschlichen Immunsystem auf zwei Arten hervor:

1.) Es aktiviert das zellulare Abwehrsystem
2.) Es aktiviert die Produktion von natürlichem Interferon, und andere Substanzen, welche das menschliche Immunsystem stärken und Viren abwehren.

CFS (Chronic fatigue System)

CFS ist eine Krankeit welche diese Folgen nach sich zieht:

Tiefe Müdigkeit, Schlafstörungen, starke Halsschmerzen, und mentale Müdigkeit und Unkonzentriertheit.

Es gibt dabei viele Symptome, welche aber von Patient zu Patient verschieden sind.

Extreme Müdigkeit nach Stess, Halsschmerzen, Kopfweh, Schwindelanfälle, erhöhte Temperatur.....

Das amerikanische Institut für Krankheiten (CDC) hat in einer Studie von 600.000 CFS-Kranken in den USA gesprochen. Die Harvard-Universität veröffentlichte eine Studie in der es um ca. 2.500.000 CFS-Kranke in den USA geht. In dieser Studie wurde auch festgehalten, dass von allen CFS-Erkrankten auf die Dauer nur bei 4 % eine Besserung ohne Behandlung eintritt. Es gibt aber bisher ausser Ampligen noch kein wirksames Mittel gegen CFS.
Zwischen 10 % bis 30 % aller Erkrankten werden zum Pflegefall.

Klinische Tests von Ampligen

HEB machte einen 24-Wochen placebo-kontrollierten Test mit 92 CFS-Erkrankten.

Die Behandlung brachte minimale bis gar keine Nebenwirkungen zum Vorschein, und war sehr postiv angenommen unter den Patienten.

Das Testergebnis:

10 % aller Patienten zeigten keine Wirkung auf die Behandlung.
60 % aller Patienten konnten zum Teil völig geheilt, aber mindestens soweit geheilt werden, dass sie ein neues Leben, weg von Pflegebedürftigkeit führen konnten.
30 % aller Patienten wurden geheilt, mussten aber nach einem Rückfall, die Behandlung wiederholen. (Dauer 9 Monate, insgesamt 24 Monate)

Die FDA hat nun bis zur vollständigen Zulassung eine weitere Testreihe unter dem IND
Status genehmigt, in dem 200 Personen behandelt werden dürfen. Bis jetzt sind alle
Medikamente, welche den IND-Status genehmigt bekamen, vollständig zugelassen
worden, und das zwischen 3 und 18 Monaten.



CFS Diagnostik-Geräte

HEB steht in Zusammenarbeit mit dem belgischen Unternehmen R.E.D Laboratories, welches
Apparate zur Diagnostizierung von CFS-Erkrankten produziert und verwendet. Bei Tests dieser Apparate wurden 92 % aller Testpersonen welche an CFS erkrankt sind entdeckt. Diese Geräte arbeiten schnell und wirkungsvoll, da sie nur die Gen-Struktur des Patienten analysieren.

Ampligen Vertrieb und Vermarktung

In den USA wird das Produkt nach der Zulassung über Olsten Corporation, die grösste amerikanische Vertriebsstelle für Medikamente mit weit über 600 Vertriebsstellen.

In Europa wird das Produkt über die zwei neu eingestellten Senior executives vertrieben, welche Zweigniederlassungen in Europa eröffnen werden.

Ampligen Produktion

Bei einer Zahlung von 3 Millionen Dollar und einer 8 % igen Beteiligung an SAB/Bioclones RNA drug sales, bekommt HEB eine exklusiv-Lizenz für eingeschränkte geographische Gebiete. Bioclones willigte ein eine Produktion zu eröffnen, in welcher HEB zu 25 % beteiligt ist, und in dieser ist es möglich bis Ende 98 Ampligen-Vorräte herzustellen, welche für über 50.000 Personen verwendbar sind.

PRODUKTE – PIPELINE von Hemispherx

Krankheit Produkt Klinischer Status

CFS Ampligen Phase II/III Komplett

Hepatitis B Polyadenur Phase III

HIV monotherapy Ampligen Phase II

HIV kombinierte Therapie Ampligen Phase II

Metastasic kidney cancer Ampligen Phase II

Malignant Melanoma Ampligen Phase II

Brust Krebs Polyadenur Phase II

Hepatitis B Oragen Preklinisch

HIV Oragen Preklinisch

Hepatitis C alle 3 Preklinisch

Polyadenur ist ein fast identisches Mittel zu Ampligen

Ampligen und Hepatitis B/C Behandlung

Marktpotential: ca. 55 Millionen Erkrankte weltweit !!!!

Das einzige Konkurrenz-Mittel ist Introgen, welches weltweit 600 Millionen Dollar alleine im Jahr 1997 an Einnahmen erbracht hat. Das Mittel wird vertrieben von Schering-Plough.

Introgen beeinhaltet viele Nebenwirkungen: Nur 25 – 40% sprechen auf eine Behandlung an davon zeigen noch einmal 25 – 40 % Nebenwirkungen und müssen die Therapie abbrechen!!!

Bei Test von Ampligen im den frühen Testphasen (jetzt) lag die Ansprechung auf die Behandlung wesentlich höher und nur 5 % mussten die Therapie mit Ampligen wegen Nebenwirkungen abbrechen.


















Die Kosten einer Ampligen-Behandlung bei CFS-Erkrankung

Eine 6-monatige Therapie kostet 7.200 $

Bei einer 4 % igen Behandlung vom gesamten Potential in den USA (mind. 500.000)
Ergibt sich folgendes:

50 % - einmalige Behandlung (6 M) 144.000.000 $
20.000 Patienten
50 % - nochmalige Behandlung (12 M) 216.000.000 $


Die Finanzzahlen entnehmen sie bitte aus der Englischen Studie www.going-public.de

[götz]

Eine kleine Neuigkeit von heute:

Hemispherx weitet seine CFS-Studien mit cost-recovery jetzt
auf Italien aus.

[derAuktionator]

Hallo Leute,
heute kam diese neue Pressemitteilung auf den Markt.

Hemispherx Affiliate Files Hepatitis C Related Notice of Invention With the U.S. Patent Office - Business Wire - 8:29 am


Tuesday January 2, 8:29 am Eastern Time
Press Release
Hemispherx Affiliate Files Hepatitis C Related Notice of Invention With the U.S. Patent Office
PHILADELPHIA--(BUSINESS WIRE)--Jan. 2, 2001--Hemispherx Biopharma, Inc. (AMEX:HEB - news; AMEX:HEBws - news) announced that the California Institute of Molecular Medicine (``CIMM``), a company in which Hemispherx is the major Corporate shareholder, has filed a Notice of Invention with the U.S. Patent Office. This notice is titled ``Replication of Human Kuppfer`s Cells obtained from HCV infected patients by Fine Needle Biopsy Technique.`` The inventors describe a new method to potentially salvage critically needed liver function without major surgery or aggressive medical intervention.
Hepatitis C is a disease of the liver caused by the Hepatitis C virus (``HCV``). Nearly four million Americans have been infected with HCV of whom 2.7 million are chronically affected. Chronic liver disease is apparent in 70% of infected persons, with current treatment regimes being effective in only 10-40% of these people.
The proprietary CIMM approach allows the in vitro growth of hepatic macrophages (called Kupffer`s cells) from the failing liver of a patient and reinfusion of liver cells into the same patient. This would not raise the question of immunological incompatibility. CIMM also advocates a process for maintaining and propagating Kuppfer`s cells (``KC``) reproducibly in defined cell cultures using fine needle liver aspirates from living human volunteers with potential for patients with failing liver due to a variety of etiologies.
KCs are one of the major components of the hepatic sinusoid. These hepatic sinusoid-lining cells actively participate in the maintenance of normal liver function, which is critical to maintaining life itself. Deterioration of KCs is implicated in the pathogenesis of both alcoholic liver disease and of chronically infected HCV patients.
Alcoholic hepatitis often leads to cirrhosis where normal liver cells are damaged and replaced by scar tissue. This is a major problem and economic burden to America, since over 25 million Americans are afflicted with liver and gallbladder diseases. Each year more the 25,000 die from chronic liver disease and cirrhosis. The only effective present treatment for the life threatening liver diseases leading to organ failure is liver transplant.
The potential market for the KC maintenance and propagation techniques will be the 14,000 people in the U.S. actively seeking a liver transplant. Additional thousands are progressing towards a failing liver and will soon need transplantation or a successful alternative method to restore function. Several hundred thousand who have alcoholic cirrhosis may also benefit from the proprietary process. Medical costs of a liver transplant are approximately $300,000 and are far beyond the financial reserves of most families.
Commenting on the development, Dr. William A. Carter, CEO of Hemispherx Biopharma, stated: ``Hepatitis C is a progressive insidious disease of the liver for which the majority of sufferers have no cure. Many hospitals refuse even to offer liver transplants to alcoholics. This proprietary propagation method for Kuppfer`s cells may offer HCV sufferers and alcoholics with significant liver damage, a chance to substantially prolong their normal liver functions.``
Similar proprietary concepts, which do not involve specific new drug applications, have been successfully used by others to treat certain human malignancies especially involving bone marrow.
Zaki Salahuddin is a preeminent researcher in virology/molecular medicine. He is the author of over 100 scientific papers and holds several dozen patents. Zaki Salahuddin worked at the National Institutes of Health (``NIH``) for many years and is very well known for his published work in the field of retro-virology (HTLV, HIV), cytokines and the discovery of human herpesvirus type-6 (HHV-6).
Information contained in this news release other than historical information including the referenced Notice of Invention should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of HEMISPHERX involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. The Company disclaims any obligation to update the forward-looking statements.

Contact:

Hemispherx Biopharma, Inc.
William A. Carter, 215/988-0080
or
Investor Relations:
Dianne Will, 214/954-9300
Fax: [phone]
or
Institutional Investors:
Mark Kollar, 212/232-2222
Fax: [phone]
HEB`s Web Site: www.hemispherx.com

[fatbull]

gibt es keine news mehr von HEMISPHERX, sind die pleite oder tauchen die wie phönix aus der asche plötzlich wieder auf ??????
würde mich über infos freuen.
vielen dank !!

mfg fatbull

[fatbull]

Thursday December 6, 11:39 am Eastern Time
Press Release
SOURCE: Hemispherx Biopharma
United States Military Sponsored Research On Hemispherx Biopharma`s Immune-Based Approach to Bioterrorism -- Smallpox -- Shows Promise
Independent Research Also Suggests Serious Side Effects Of Smallpox Vaccine May Also Be Reduced; Company Continuing Advanced Clinical Trials in HIV/AIDS And Chronic Fatigue Syndrome
PHILADELPHIA--(BUSINESS WIRE)--Dec. 6, 2001-- Hemispherx Biopharma, Inc. (AMEX:HEB - news), a leading company in the development of immune based therapies primarily addressing the diseases of Chronic Fatigue Syndrome and HIV AIDS indicated today, in response to inquiries on its bioterrorism program, that positive results have already been obtained from independent animal-based research performed at the Arbovirus Unit of Yale University in collaboration with the United States Army Medical Research Institute for Infectious Diseases regarding the efficacy a member of the Company`s RNA drug platform, Ampligen® for the treatment of smallpox.

Ampligen®, performed better than any of the other chemo-therapeutics in terms of reducing the number and severity of pox lesions (or severe skin sores) on the test animals. Ampligen® is in Phase III clinical trials in CFS and Phase IIB in HIV/AIDS.

The virus used, termed ``Vaccinia Virus`` is closely related to Smallpox virus. Indeed, Vaccinia Virus has been regularly injected into U.S. Military personnel to convey immunity against Smallpox. In the model Smallpox system, Vaccinia Virus caused skin lesions, or severe skin inflammations, whose severity was based on the particular virulence of the various strains of virus used.

According to the researchers ``Ampligen® suppressed (inhibited) the lesions at very low doses.`` The researchers also undertook the studies to determine if various test medications (of which there were approximately 15 including RNA drug platform, Ampligen®), could lessen the potential dreaded side effects of Smallpox vaccination. The side effects include rapid spread of the virus from the vaccination site leading to death and other very serious complications.

In the United States alone, it is estimated that there are millions of people who are unable to take vaccination unless they would be protected from the dreaded vaccine side effects; this population includes patients with cancer, AIDS, organ transplantation and pregnant women.

The Company stated that, in view of the thousands of viruses which exist in nature, studies such as those conducted by the Military are necessary to evaluate therapeutic potential of any new drug or immunotherapeutic. In contrast, potential benefit may not be extrapolated from viruses which are unrelated to Smallpox, as has been recently reported in the public environment of growing concern for renewed bioterrorism, especially Smallpox.

The scientific article is entitled ``Chemotherapeutic Prevention of Complications Caused by Vaccinia Virus-Vectored Immunogen`` and is co-authored by scientists at the Yale Arbovirus Research Unit, Yale University School of Medicine, New Haven, CT and the U.S. Army Medical Research Institute of Infectious Diseases, Fort Dietrich, Frederick, MD. The results of the research are available in The Annals of the New York Academy of Sciences, Vol 653, and pages 334-343.

The research was supported by contract DAMD17-86-C-6042 of the U.S. Research and Development Command, Fort Dietrick, Frederick, MD.

The Company stated that these studies represented an example of successful outsourcing of research based on the sustained scientific interest and the Company`s unique approach to immunotherapy of various viral diseases. The Company`s core programs in CFS treatment and HIV treatment are managed internally while ancillary programs are typically implemented by collaborative research agreements.

The Company also indicated that while it is responding to the potential needs of the current emergencies in the aftermath of the events of September 11th 2001 with limited and strategic investigations into the use of its platform technology for the treatment of terroristically induced pathogens, it continues to focus its principal energies on the currently pending phase III clinical trials for its platform drug RNA drug platform, Ampligen®, and for the treatment of chronic fatigue syndrome and its phase IIB trials of the same drug for HIV/AIDS.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including CFS, HIV and hepatitis. Its flagship products are Ampligen® -- being developed for CFS and drug resistant HIV -- and Polyandenur being developed for hepatitis B and C. It is conducting phase III trials in CFS and phase IIb trials in HIV/AIDS. For more information visit the company`s Web site at www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.



--------------------------------------------------------------------------------
Contact:

Hemispherx Biopharma, Philadelphia

[Kaligula]

Hemispherx and The AIDS Community Research Initiative of America -- ACRIA -- Launch Immunotherapeutic HIV/AIDS Clinical Trials in New York City Trials Will Explore Use Of Ampligen(R) In Both "Salvage" And "Strategic Interruption" Studies

PHILADELPHIA, Apr 18, 2002 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, and the AIDS Community Research Initiative of America, (ACRIA), a leading independent, nonprofit community based AIDS research and treatment education organization, announced today , the initiation of clinical trials designated, AMP 719 and 720 involving the application of Hemispherx`s experimental drug Ampligen(R ) for the treatment of HIV/AIDS.
With regard to "Strategic Therapeutic Interruptions" (STIs) -AMP 720- the trial will study whether Amplgen(R), an experimental agent, can assist the immune systems response to a carefully monitored interruption of the widely used Highly Active Anti Retroviral Treatments (commonly known as " HAART" or "Cocktail" treatments).

With regard to "Salvage Therapy" -AMP 719 -- the trial will study whether Amplgen(R), as an experimental agent, can resensitize the immune system to certain of the HAART or cocktail regimens to which it has become desensitized by reason of the HIV virus having mutated into a drug resistant strain.

Dr. Jerome Ernst, MD, Medical Director of ACRIA, commented on the Strategic Interruption study as follows, " Ampligen(R) is an immunomodulator with a low incidence of side effects. It can stimulate interferon and other cytokines, as well as other intracellular antiviral defense mechanisms. The theory is that Ampligen(R) will lengthen the HAART-free time interval with a resultant decrease in HAART-induced toxicities. The hope is that Ampligen(R) may maximize STIs to the point that the cell -- mediated immune system responses might be sufficient to eliminate the need for HAART."

Regarding the "salvage" study Dr. Ernst added, "Here again because of Ampligen(R)`s ability to stimulate interferon, other cytokines and other intracellular antiviral defense mechanisms, the hope is that Ampligen(R) may resensitize the immune systems of individuals who are failing on certain of the HAART regimens because the virus has mutated to a form that is resistant to the HAART regimen. This possibility is highly significant since approximately 50 percent of all patients currently on HAART have developed a virus strain which is resistant to two or more of the HAART regimens"

Commenting on the timing of enrollment and the number of participants, Dr. Ernst concluded by saying, "ACRIA is a highly respected independent, nonprofit, community - based AIDS research and treatment education organization. We are dedicated to improving the length and quality of life for people living with HIV/AIDS. In this capacity we are eager to study new treatments for HIV and related diseases through Clinical research and the conduct of comprehensive treatment education programs. Because of our long-standing reputation in the HIV/AIDS community we are confident that we will rapidly enroll a large number of persons for the studies and successfully assist a very high percentage of these persons through to the completion of the trials."

Dr. William Carter, CEO and Chief Scientific Officer of Hemispherx, added "The addition of ACRIA to our six existing HIV/AIDS clinical trial sites represents a landmark achievement regarding our activities in the HIV/AIDS arena. It is our first HIV/AIDS clinical trial based directly in New York City. Moreover it associates us with a premier nonprofit organization serving the HIV/AIDS community. We believe that not only will ACRIA rapidly enroll and guide to successful completion a large number of trial participants, but that ACRIA`s participation in the trials will accelerate the enrollment in our existing clinical trial sites and the securing of further new clinical trial sites."



ABOUT ACRIA

The AIDS Community Research Initiative of America (ACRIA) (www.acria.org) is a non-profit community-based AIDS research and treatment education center. Since 1991, ACRIA has been dedicated to developing effective treatments for HIV disease and to examining therapies which minimize toxic side effects of antiretroviral drugs. ACRIA works closely with prominent researchers at teaching hospitals and other community based clinics nationwide to conduct innovative independent protocols as well as with the pharmaceuticals industry to test new experimental treatments in Phase III trials In conjunction with recognized leaders in AIDS research and treatment, primary-care providers, and people living with HIV disease; ACRIA:


-- identifies scientifically promising therapies for AIDS and
HIV-related illness, designs and implements studies on these
interventions, and submits the findings for publication;
-- conducts research geared towards the further understanding of
HIV disease, treatment, and prevention; and
-- provides education about AIDS treatments and research to the
communities affected by HIV/AIDS.
About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company`s Web site at www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.



CONTACT: Hemispherx Biopharma, Inc.
William A. Carter, M.D.
Chairman & CEO
Tel: [phone]
Fax: [phone]
or
MRB Investor Relations, LLC
Robert Giordano
Tel: [phone]
Fax: [phone]
E-mail: [e-mail]
or
Dianne Will
518-399-6222
E-mail:[e-mail]
HEB`s Web Site: www.hemispherx.net

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

-0-

KEYWORD: PENNSYLVANIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
PHARMACEUTICAL
SOURCE:
Hemispherx
Biopharma,
Inc.

Gruss
Kali

[fatbull]

Monday April 29, 8:57 am Eastern Time
Press Release
SOURCE: Hemispherx Biopharma, Inc.
Hemispherx Announces Formation of Committee to Initiate Search For Medical Director to Lead its New HIV/AIDS Division
Clinical Results To Date Accelerate Patient Accrual and Expand Programs
PHILADELPHIA--(BUSINESS WIRE)--April 29, 2002-- Hemispherx Biopharma, Inc (AMEX:HEB - news), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today the formation of an Executive Committee to initiate a search to fill the newly created position of HIV/AIDS Medical Director.

In March of this year, the company presented data at the International Antiviral Conference held in Prague, the Czech Republic, regarding preliminary results of its Phase IIb clinical trials for HIV/AIDS involving the use of its lead experimental immunotherapeutic, Ampligen. Subsequent to the publications of these clinical data, enrollment of new patients and new clinical trial sites has rapidly accelerated. Most recently, the Company has added to its clinical trial sites the prestigious AIDS Community Research Initiative of America (ACRIA), a leading independent, nonprofit community based AIDS research and treatment education organization, based in New York City.

The Search Committee will be co-chaired by Mr. Peter Vansteenkiste, a management consultant based in New York and Belgium with significant expertise and interested in the field of scientific discovery and clinical research, and Ransom W. Etheridge, Esq., a member of the Company`s Board of Directors, will also lead the effort.

"The accelerating enrollment of new patients and establishment of new clinical trial sites has created the need for a Medical Director fully dedicated to the progress in the Company`s HIV/AIDS clinical trials" said Ransom W. Etheridge, Esq.

"The candidate for the new position will assume supervision for the Company`s HIV/AIDS clinical trials, thereby permitting Dr. Strayer to concentrate more fully on the Company`s Chronic Fatigue Syndrome Phase III clinical trial." explained Mr. Peter Vansteenkiste.

The Company plans to present updated clinical results of these ongoing trials at the XIV International AIDS Conference in Barcelona Spain, July 7 - 12.

Hemispherx Biopharma, Inc., Philadelphia, PA, has devoted nearly three decades to exploring, understanding, and mastering the mechanism of ribonucleic acid (RNA) drug technology. The Company`s longevity as a biomedical research and drug development institution, coupled with its record of enduring scientific achievement, is evidence of long-term commitment to these promising new classes of drugs for the chronically ill and to bring new therapeutic choices to the global health care community. For more information, please visit the Company`s website at http://www.hemispherx.net.

Information contained in this news release other than historical information, should all be considered forward-looking and are subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgement as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.



--------------------------------------------------------------------------------
Contact:

William A. Carter, MD
215/988-0080; Fax: [phone]
Dianne Will, Tel: [phone]; E-mail: [e-mail]
or
MRB Investor Relations, LLC

[jump1971]

guten Morgen!nachdem,der kurs jetzt bei 1,05$ liegt....überwiegen doch die Chancen wieder1?Oder?Wie,hoch ist die mkap.?Wieviele andere Firmen forschen an den selben Stoffen?ohne,risiko auf Totalverlusst,geht heut eh nix mehr...Wie,seht,Ihr das???mit frdl. Grüßen...jump!

[xanda1]

taglich brothers haben kürzlich das
kursziel von $13 auf nun $21 angehoben.

begründet wurde dies damit, dass eine
zulassung eines medikamentes bevorstehen
sollte.

wie auch immer, von mir aus kann es losgehen.

[kurttilly]

Meldung schon vor ca. 4 Wochen bei GBI; Kurs bröckelt so langsam von 3,00 € zurück, um Luft zu holen für seinen rasanten Aufstieg !!

[kurttilly]

Die "Kleinen" habens heute in sich!!!
Wie ich in meiner letzten Antwort feststellte: bröckelt langsam ab, um mit Schwung zu steigen.!

Seht auch Elan Corp.!!!

[xanda1]

Press Release Source: Hemispherx Biopharma, Inc.


Hemispherx Biopharma Completes Full Enrollment of its Phase III Clinical Trial for Chronic Fatigue Syndrome (CFS)
Monday December 9, 9:27 am ET
First Ever Completely Enrolled Phase III Clinical Trial for Disorder Affecting Over 500,000 Americans Surpasses Enrollment Target; Data Analysis Expected in 2003

http://biz.yahoo.com/bw/021209/92253_1.html

[kurttilly]

Schon lange nichts mehr von Hemispherx gehört. Weiß jemand etwas Neues??